Periprosthetic Joint Infection Bubble Study

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorThomas Jefferson University

About this trial

Patients with an infected knee replacement will receive their standard of care surgical treatment of the infection, with and without additional ultrasound microbubble treatment (randomly divided 50/50 in the active and control groups). Subjects in the active group will receive a local bolus injection of antibiotics and ultrasound-active microbubbles within 24 hours of their revision surgery. The fundamental hypothesis is that a decrease in re-infection rates of at least 24% can be achieved in the active group relative to controls.

Eligibility criteria

Qualifiers

Be at least 18 years of age

Be medically stable

If female of child-bearing potential, must have a negative pregnancy test

Be conscious and able to comply with study procedures

Disqualifiers

Females who are pregnant or nursing

Patients currently on chemotherapy requiring systemic treatment

Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable

Patients with a history of anaphylactic allergy to perflutren or any other components of Definity

Trial design

Treatments tested in this trial

  • Ultrasound-triggered microbubble destruction with antibiotics

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Thomas Jefferson University

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator